U.S. markets open in 6 hours 5 minutes

Atreca, Inc. (BCEL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
13.45-0.26 (-1.90%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close13.71
Open13.78
Bid0.00 x 1200
Ask0.00 x 4000
Day's Range13.21 - 13.95
52 Week Range9.51 - 29.35
Volume189,222
Avg. Volume343,512
Market Cap484.595M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-6.36
Earnings DateAug 12, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est28.86
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Is Atreca, Inc. (NASDAQ:BCEL) Popular Amongst Institutions?
    Simply Wall St.

    Is Atreca, Inc. (NASDAQ:BCEL) Popular Amongst Institutions?

    The big shareholder groups in Atreca, Inc. (NASDAQ:BCEL) have power over the company. Insiders often own a large chunk...

  • GlobeNewswire

    Atreca to Present at Two Upcoming Virtual Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in the following upcoming virtual investor conferences:  H.C. Wainwright & Co. 22nd Annual Global Investment Conference 2020 Wednesday, September 16, 2020 Presentation time: 3:30 p.m. EDTMorgan Stanley Virtual Global Healthcare Conference 2020 Thursday, September 17, 2020 Presentation time: 3:30 p.m. EDTA live audio webcast of each presentation can be accessed through the Events & Presentations section of the Company's website at ir.atreca.com. An archived replay of each webcast will be available on the Company's website for 90 days following the live presentations.About Atreca, Inc. Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca’s platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.Contacts Atreca, Inc. Herb Cross Chief Financial Officer info@atreca.com Investors: Alex Gray, 650-779-9251 agray@atreca.comMedia: Sheryl Seapy, 213-262-9390 sseapy@w2ogroup.com Source: Atreca, Inc.

  • Atreca, Inc. (BCEL) Upgraded to Buy: Here's Why
    Zacks

    Atreca, Inc. (BCEL) Upgraded to Buy: Here's Why

    Atreca, Inc. (BCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).